Daratumumab

Grey

Brand Name(s):Darzalex

Indication:Multiple Myeloma

Rationale:2

Considered:Jul-16

Review Date:Sep-24

Comments:
Drug Safety Update Aug 19; Daratumumab (Darzalex?): risk of reactivation of hepatitis B virus
Establish hepatitis B virus status before initiating daratumumab and in patients with unknown hepatitis B virus serology who are already being treated with daratumumab.
…………………………………… NICE TA454
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Jul-17